Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: Psychological aspects of physician-patient communication

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1647-1652

  Costantini, A ^a   Picardi, A ^b   Zilli, M ^c   Cairoli, F ^a   Torta, R ^d   Marchetti, P ^e   Baile, W ^f   Iacobelli, S ^c,g  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Inter University Consortium for Bio Oncology G D'Annunzio   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF CHIETI   (Italy)

Author keywords

Breast cancer; Hormonal switch; Patient anxiety; Physician patient communication; Recurrence risk

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTICLE; ATTITUDE TO CHANGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; COMMUNICATION SKILL; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; ITALY; MALE; OPEN ENDED QUESTIONNAIRE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; STRUCTURED QUESTIONNAIRE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; HUMANS; ITALY; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL; TAMOXIFEN;

EID: 70349646319     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp057     Document Type: Article

References (30)

1. Fallowfield L, Jenkins V. Effective communication skills are the key to good cancer care. Eur J Cancer 1999; 35(11): 1592-1597.
2. Fallowfield L, Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet 2004; 363(9405): 312-319.
3. Stewart MA. Effective physician-patient communication and health outcomes: A review. CMAJ 1995; 152(9): 1423-1433.
4. Buckman R. Communications and emotions. BMJ 2002; 325(7366): 672.
5. Buckman R. How to Break bad News: A Guide for Health Care Professionals. Baltimore, MD: Johns Hopkins University Press 1992; 15.
6. Baile WF, Buckman R, Lenzi R et al. SPIKES-A six-step protocol for delivering bad news: Application to the patient with cancer. Oncologist 2000; 5(4): 302-311.
7. Fallowfield L, Jenkins V, Farewell V et al. Efficacy of a Cancer Research UK communication skills training model for oncologists: A randomised controlled trial. Lancet 2002; 359(9307): 650-656.
8. Razavi D, Merckaert I, Marchal S et al. How to optimize physicians' communication skills in cancer care: Results of a randomized study assessing the usefulness of posttraining consolidation workshops. J Clin Oncol 2003; 21(16): 3141-3149.
9. Baile WF, Fryer-Edwards K, Back A et al. Teaching communication skills to oncology fellows: The ABC's of using psychodynamic principles. Psychooncology 2005; 14 (Suppl 12): IV-1.
10. Delvaux N, Merckaert I, Marchal S et al. Physicians' communication with a cancer patient and a relative: A randomized study assessing the efficacy of consolidation workshops. Cancer 2005; 103(11): 2397-3411.
11. Back AL, Arnold RM, Baile WF et al. Efficacy of communication skills training for giving bad news and discussing transitions to palliative care. Arch Intern Med 2007; 167(5): 453-460.
12. Costantini A, Baile W, Costantini M et al. Overcoming cultural barriers to giving bad news: Feasibility of training to promote truth-telling to cancer patients. J Cancer Educ; in press.
13. Wengström Y, Aapro M, Leto di Priolo S et al. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. Breast 2007; 16(5): 462-468.
14. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16(2): 515-521.
15. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006; 42(14): 2271-2276.
16. Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: Results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 2007; 5(3): 139-143.
17. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21(4): 602-606.
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365(9472): 1687-1717.
19. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008; 26(5): 798-805.
20. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol 2006; 7(12): 991-996.
21. Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007; 25(5): 486-492.
22. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007; 369(9561): 559-570.
23. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9(1): 45-53.
24. Lin NU, Winer EP. Optimal use of aromatase inhibitors: To lead or to follow? J Clin Oncol 2007; 25(19): 2639-2641.
25. Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J Clin Oncol 2007; 25(19): 2664-2670.
26. Iddon J, Bundred NJ. To switch or not to switch: Should the updated Intergroup Exemestane Study alter our decision? Expert Rev Anticancer Ther 2008; 8(1): 9-13.
27. Keating NL, Guadagnoli E, Landrum MB et al. Treatment decision making in early-stage breast cancer: Should surgeons match patients' desired level of involvement? J Clin Oncol 2002; 20(6): 1473-1479.
28. Leighl N, Gattellari M, Butow P et al. Discussing adjuvant cancer therapy. J Clin Oncol 2001; 19(6): 1768-1778.
29. Bruera E, Willey JS, Palmer JL, Rosales M. Treatment decisions for breast carcinoma: Patient preferences and physician perceptions. Cancer 2002; 94(7): 2076-2080.
30. Siminoff LA, Fetting JH, Abeloff MD. Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 1989; 7(9): 1192-1200.